CYTOCHROME P A (CYPA) substrates WITH narrow therapeutic indices: patients chronically receiving medications known to be metabolized by CYPA and with narrow therapeutic indices within  days prior to study enrollment, including but not limited to pimozide, aripiprazole, triazolam, ergotamine and halofantrine are not eligible; Note: the use of fentanyl is permitted
Patients must be able to discontinue CYPC substrates with a narrow therapeutic index (e.g. warfarin, phenytoin), if randomized to TGR-; patients must discontinue such agents at least  week or  half-lives prior to beginning protocol therapy (whichever is longer)
Cytochrome P, family , subfamily A, polypeptide  (CYPA) substrates with narrow therapeutic indices: Patients chronically receiving medications known to be metabolized by CYPA and with narrow therapeutic indices including pimozide, aripiprazole, triazolam, ergotamine and halofantrine are not eligible; the topical use of these medications (if applicable) is allowed
Sensitive or narrow therapeutic range substrates of CYPD
An oral medication with a narrow therapeutic index known to be a P-gp substrate within  hours prior to start of dosing in the study
Require continued treatment with a medication that is a sensitive CYPC substrate with a narrow therapeutic index.
known P gp substrates with a narrow therapeutic index
Concurrent use of CYPA substrates with narrow therapeutic indices within  days prior to the first dose of lorlatinib or crizotinib.
Patients may not be receiving any other investigational agent for any purpose concurrently; patients may not require ongoing treatment with (a) gastric pH modifying medications including proton pump inhibitors or H blockers (patients may switch to antacids), (b) medications which are known to be sensitive substrates or substrates with a narrow therapeutic index for the P-gp and BCRP transporters and/or (c) medications known to cause corrected QT (QTc) prolongation with risk of Torsades
Treatment with any medication which is predominantly metabolized by CYPA and has a narrow therapeutic index.
Is chronically taking a sensitive CYPA substrate or a CYPA substrate with a narrow therapeutic index and cannot be switched to an alternative agent at least  days prior to study initiation that in the opinion of investigator/treating physicians precludes utilization of idelalisib
Drugs which are substrates for the drug transporter multidrug resistance protein  (MDR) have a narrow therapeutic window; or which are strong inhibitors of drug transporter MDR.
Avoid co-administration of abiraterone acetate with CYPD substrates that have a narrow therapeutic index. If an alternative treatment cannot be used, exercise caution and consider a dose reduction of the concomitant CYPD substrate
Warfarin or other Vitamin K antagonists treatment, strong inhibitors or inducers of cytochrome P (CYP)A, and drugs with a narrow therapeutic index, which are predominantly metabolized by CYPA and drugs known to have a high risk to prolong QTc as per label.
Avoid co-administration of abiraterone acetate with CYPD substrates that have a narrow therapeutic index. If an alternative treatment cannot be used, exercise caution and consider a dose reduction of the concomitant CYPD substrate.
Patients taking medications with a narrow therapeutic index including warfarin, digoxin, phenobarbital, carbamazepine, and cyclosporine are not excluded but should be monitored carefully.
Treatment with any medication which is predominantly metabolized by CYPA and has a narrow therapeutic index.
An oral medication with a narrow therapeutic index known to be a P-gp substrate within  hours prior to start of dosing in the study
Treatment with any medication which is predominantly metabolized by CYPA and has a narrow therapeutic index
known to be substrates of CYPA/ and P-gp with a narrow therapeutic index
Avoid co-administration of abiraterone acetate with CYPD substrates that have a narrow therapeutic index; if an alternative treatment cannot be used, exercise caution and consider a dose reduction of the concomitant CYPD substrate
Drugs known to be CYPA substrates with narrow therapeutic windows (such as alfentanil, astemizole, cisapride, dihydroergotamine, pimozide, quinidine, sirolimus, or terfanide) or CYPC substrates are not allowed; patients must be switched to alternative drugs at least  days prior to receiving the first dose of AMG ; those patients who cannot switch to alternative drugs will be excluded from the study
Use of any known CYPA substrates with narrow therapeutic window (such as alfentanil, astemizole, cisapride, dihydroergotamine, pimozide, quinidine, sirolimus, or terfanide) within the  days prior to receiving the first dose of AMG  is not permitted; other medications (such as fentanyl and oxycodone) may be allowed per investigators assessment/evaluation
Patients chronically receiving medications known to be metabolized by cytochrome P , family , subfamily A, polypeptide  (CYPA) and with narrow therapeutic indices including pimozide, aripiprazole, triazolam, ergotamine and halofantrine are not eligible; the topical use of these medications (if applicable) is allowed
As PF- is an inhibitor of cytochrome P, family , subfamily A, polypeptide  (CYPA), patients chronically receiving medications known to be metabolized by CYPA and with narrow therapeutic indices including pimozide, aripiprazole, triazolam, ergotamine and halofantrine are not eligible; the topical use of these medications (if applicable) is allowed
Concomitant use of agents with narrow therapeutic windows that are metabolized by CYPA, cytochrome P D (CYPD), or cytochrome P C (CYPC) is not recommended
Participants taking medications that are known potent CYPA inducers/inhibitors or substrates with narrow therapeutic indices or St. John's Wort.
Medications that have a narrow therapeutic window and are predominantly metabolized through CYPA/
Those have a narrow therapeutic window and are predominantly metabolized through CYPA/.
Use of any known CYPC substrates with a narrow therapeutic window is not allowed during the study and patients must come off  days prior to receiving the first dose of AMG 
Use of any known CYPA substrates with narrow therapeutic window (such as alfentanil, astemizole, cisapride, dihydroergotamine, pimozide, quinidine, sirolimus, or terfanide) within the  days prior to receiving the first dose of AMG ; other medications (such as fentanyl and oxycodone) may be allowed per investigators assessment/evaluation
Patients requiring medications metabolized through CYPA/ and have a narrow therapeutic index or medications that are CYPA substrates that cause QT prolongation
Patients requiring medications that are sensitive CYPD substrates areCYPD substrates with a narrow therapeutic index or are anti-arrhythmic drugs/drugs with QT-prolongation risks
Patients requiring medications with narrow therapeutic index CYPA substrates
Substrates of CYPD with a narrow therapeutic index (eg, thioridazine);
That have a narrow therapeutic window and are predominantly metabolized through CYPA.
CYPA substrates with narrow therapeutic index
Patients taking medications with narrow therapeutic indices that are metabolized by cytochrome P (CYP), including warfarin sodium (Coumadin) are ineligible
All subjects must agree to stop the use of any known CYPA substrates with narrow therapeutic window (such as alfentanil, astemizole, cisapride, dihydroergotamine, pimozide, quinidine, sirolimus, or terfanide; within the  days prior to receiving the first dose of AMG  and during protocol AMG  treatment (weeks -); other medications (such as fentanyl and oxycodone) may be allowed per investigators assessment/evaluation
All subjects must agree to stop the use of any known CYPC substrates with a narrow therapeutic window within the  days prior to receiving the first dose of AMG  and during protocol AMG  treatment (weeks -)
CYPA or CYPC or P glycoprotein (P-gp) or breast cancer resistance protein (BCRP) substrates having a narrow therapeutic index;
Ongoing treatment with CYPA substrate with narrow therapeutic range at the start of study treatment
Patients who are currently receiving treatment with agents that are metabolized predominantly through CYPA and that have a narrow therapeutic window.
Permeability-glycoprotein (P-gp) substrates with a narrow therapeutic index
Use of drugs metabolized by CYPD; these are called CYPD substrates
On scheduled CYPA substrates with narrow safety range at the time of study enrollment (alfentanil, cyclosporine, dihydroergotamine, ergotamine, pimozide, quinidine, sirolimus, tacrolimus)
Use of any drugs or substances known to be CYPA substrates with narrow therapeutic range within  week prior to Day , or planned to be used during the overall study period.
Concurrent use of drugs that are CYPA substrates with narrow therapeutic indices such as astemizole, terfenadine, cisapride, pimozide, quinidine, tacrolimus, cyclosporine, sirolimus, (alfentanil and fentanyl, including transdermal patch) or ergot alkaloids (ergotamine, dihydroergotamine) should be used with caution
Concurrent use of drugs that are CYPC substrates with narrow therapeutic indices, such as warfarin, phenytoin or a sensitive substrate such as celecoxib should be used with caution
Use of drugs that are CYPA substrates with narrow therapeutic indices, including but not limited to dihydroergotamine, ergotamine, and pimozide.
CYPA substrates with narrow therapeutic window (including, but not limited to, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus).
